Proof-of-concept Study of BI 655130 add-on Treatment in Patients With Mild-to-moderately Active Ulcerative Colitis During TNF Inhibitor Therapy
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2018
At a glance
- Drugs BI 655130 (Primary)
- Indications Ulcerative colitis
- Focus Proof of concept; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 03 Jul 2018 This study has been suspended in Spain.
- 29 Jun 2018 This study has been changed from suspended to recruiting in Germany.
- 09 Jun 2018 This trial has been changed from Suspended recruiting in Denmark, according to European Clinical Trials Database